Healthcare / BiotechnologyNasdaqGS
$8.98
+0.53 (+6.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-111.7M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$930M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.7%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-129.5M · FCF $-111.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Net Income | $-129.5M | $-129.5M | $-127.8M | $-100.7M | $-89.1M | $-78.7M | $-73.7M | $-26.9M | $-21.4M |
| EBITDA | $-141.8M | $-141.8M | $-141.8M | $-109.7M | $-85.8M | — | — | — | — |
| EPS | — | — | -1.83 | -1.96 | -2.25 | -2.07 | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | — | — | — |
| Current Ratio | 16.33 | 16.33 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-111.7M | $-111.7M | $-113.8M | $-86.5M | $-77.2M | $-60.5M | $-45.9M | $-24.3M | $-21.2M |
| Returns | |||||||||
| ROE | -33.7% | -33.7% | -52.6% | -44.9% | -40.1% | -28.8% | -25.4% | 29.8% | 33.2% |
| Valuation | |||||||||
| P/B | 2.30 | 2.30 | 2.45 | 1.93 | 1.01 | — | — | — | — |
| Growth & Yield | |||||||||
| EPS Growth | — | — | 6.6% | 12.9% | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.83 → n/d
Residual
+9.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.